Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://ih.advfn.com/stock-market/NASDAQ/inmed-pharmaceuticals-INM/stock-news/86946860/inmed-issues-annual-letter-to-shareholders-highlig
Accomplishments my Butt
All they've managed to accomplish is take the share price from $6.42 to 1.25 in less than a year.
POS
InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference
InMed Pharmaceuticals Inc.
Tue, November 23, 2021, 6:30 AM
In this article:
INM
+0.28%
Explore the topics mentioned in this article
VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on November 29 – December 1, 2021.
Cowen's 4th Annual Cannabis Conference
Date: November 29 - December 1, 2021
Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Cowen institutional representative or visit the conference website at https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/
Cowen’s 4th Annual Cannabis Conference is a three-day conference comprising of topical panel discussions with C-Suite presenters, hosted by Cowen Research and Washington Research Group analysts, and virtual one-on-one meetings.
About InMed: InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Senior Director, Investor Relations
T: +1 604 416 0999
E: cclancy@inmedpharma.com
Edison Group:
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: jgreen@edisongroup.com / lyonker@edisongroup.com
InMed Pharma_soars_after_releasing_extracts_from_research_report
Nov. 17, 2021 11:26 AM ETInMed Pharmaceuticals Inc.
Merger Acquisition
InMed Pharmaceuticals (INM +50.7%) has added more than a third in value after posting excerpts from a research report that illustrated a “substantially different profile” for the company from a few months ago.
In the report, commissioned by InMed (NASDAQ:INM), Edison Investment Research has adjusted the company valuation to $290m or $20.53 per basic share from $293m or $24.24 per basic share previously. Edison attributes its decision mainly to an increase in the number of shares outstanding following the closure of InMed’s (INM) BayMedica acquisition.
The company stock closed at $1.40 per share on Tuesday.
The firm also estimates InMed’s (INM) will raise an additional $11M in FY23 and notes that the exact amount of funding will depend on the expenditure for the combined business.
In October, InMed (INM) announced that it completed the acquisition of BayMedica, a U.S.-based company focused on the production and commercialization of cannabinoids.
$INM-Week of September 13, 2021
Date Requested September 13, 2021
https://investors.inmedpharma.com/stock-information?_ga=2.116335617.62463903.1631732122-1701746093.1631732122
Open Price USD
$2.12
Closing Price
$2.05
Day's High
$2.12
Day's Low
$2.01
Volume
124,096
Split Adjustment Factor
1:1
$IMN Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2020 6:22:27 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2020 6:21:18 AM
$IMN Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2020 6:19:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2020 6:18:36 AM
$INM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2020 6:17:24 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2020 6:16:19 AM
$INM Quarterly Report (10-q) Edgar (US Regulatory) - 12/17/2020 6:04:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/4/2020 1:49:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/3/2020 12:59:49 PM
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids PR Newswire (Canada) - 12/3/2020 7:30:00 AM
InMed Pharmaceutical (INM)
3.48 ? -0.01 (-0.29%)
Volume: 42,381 @01/05/21 11:48:28 AM EST
Bid Ask Day's Range
3.48 3.51 3.42 - 3.5767
INM Detailed Quote
what's up with INM - love the tech, hating the PPS
IMN data from FINRA Daily List 11/12/20 1:45:55 AM
Date/Time Event Type Eff/Ex Date/Time Symbol Issue Name Market
11/12/2020 01:45:55 Market Center Change Listed on NASDAQ 11/12/2020 01:45:55 IMLFF InMed Pharmaceuticals, Inc. Common Stock Other OTC
Comments
Prdct chng OTCE-OTCE>UTP-NSDQ
Details
Current Value
Daily List Date/Time 11/12/2020 01:45:55
Event Type Market Center Change Listed on NASDAQ
Effective/Ex Date/Time 11/12/2020 01:45:55
Symbol IMLFF
Issue Name InMed Pharmaceuticals, Inc. Common Stock
Class
Market Category Other OTC
Offering Type No Restrictions
Daily List Comment Prdct chng OTCE-OTCE>UTP-NSDQ
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020
https://marketwirenews.com/news-releases/inmed-reschedules-reporting-of-first-quarter-financi-8615275889989666.html
News: InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
https://ih.advfn.com/stock-market/NASDAQ/inmed-pharmaceuticals-INM/stock-news/83669978/inmed-announces-pricing-of-us-8m-public-offering-a
International Northair Completes Surface Access and Rights Agreements at the La Cigarra Silver Project, Mexico
Sept 11, 2013
http://www.internationalnorthair.com/s/news.asp?ReportID=602693
Latest INM corporate presentation
http://www.internationalnorthair.com/i/pdf/Presentation/presentation.pdf
19.4% ownership of INM by Coeur Mining, (formerly Coeur d’Alene Mines) following closing of placement in July 2013.
International Northair Mines Closes Oversubscribed Private Placements for $1.8 Million
http://www.internationalnorthair.com/s/news.asp?ReportID=594196
INM Video Presentation
Chris Curran, Manager Corporate Communications for International Northair Mines gave a presentation at the 2012 Subscriber Investment Summit.
Click Here To Watch The International Northair Mines Video Presentation
Interesting......(INM.V)
Paul Dircksen
Position: Director
Mr. Dircksen is the Executive Chairman & Director of Timberline Resources Corporation, which is targeting production in 2010 from its Butte Highlands underground gold property in Montana. Paul has over 35 years of experience in the mining and exploration industry which includes serving in executive, managerial and technical roles at a number of companies. Mr. Dircksen has a strong technical background that was fostered by serving as a team member on nine gold discoveries, seven of which later became operating mines. He has held senior management positions with Lacana Gold, the Cordex Syndicate, Orvana Minerals, Bravo Venture Group, and Brett Resources. Mr. Dircksen has an M.S. in Geology from the Mackay School of Mines at the University of Nevada.
http://www.internationalnorthair.com/s/Directors.asp
Northair Intersects 48.05 Metres of 140.6 g/t Silver at La Cigarra Project, Mexico
Northair Completes Oversubscribed Private Placement for + $5 Million
Northair Intersects 80.45 Metres of 123.5 g/t Silver at La Cigarra Silver Project, Mexico
International Northair Mines Ltd. (TSX VENTURE:INM - News; the "Company" or "Northair") is pleased to announce assay results from the first two holes of the current Phase II core drill program at the La Cigarra silver project located in north central Mexico. Drill highlights of the program to date include 80.45 meters of 123.5 g/t silver in Hole CC-11-002 at the San Gregorio Zone.
El Tesoro Project, Durango, Mexico
website update...
The Company has acquired a large property position covering multiple high grade gold occurrences.
Property Details:
El Tesoro is an undeveloped and relatively unrecognized gold district. To date, seven distinct zones of vein type mineralization have been identified within a currently defined belt approximately 2.5 kilometers long and up to 600 meters wide.
Mineralization occurs in classic high level, low sulfidation, epithermal vein type systems, generally associated with rhyolitic dikes and plugs intruding coeval welded rhyolitic volcanics. The mineralized zones consist of quartz stockwork and fine-grained silicified breccia located along north-northwesterly, northerly and northeasterly trending faults. The mineralized zones manifest many of the features commonly associated with epithermal systems such as vuggy and drusy veins, open space fillings, cockade and banded textures, amethystine quartz, and multiple silicification and brecciation events. Widths of known veins range from about 1.0 to 20 meters. Strike lengths have yet to be determined due to extensive post-mineral cover.
The Company believes there is excellent potential for defining significant reserves that could be mineable by standard underground and open pit methods. There is substantial exploration potential for the discovery of additional mineralized areas both on strike with the known zones, as well as laterally, since much of the concession area is obscured by a cover of post-mineralization volcanics and surficial deposits.
Summary of Work to Date:
The El Tesoro Project area was identified by Northair exploration staff during 2002 as part of the Company’s ongoing generative exploration program. Initial sampling reported high grade gold values up to 55 g/t. The Company immediately initiated land status research and acquisition programs to consolidate ownership of the district. Three concessions were staked by Northair’s exploration team, and an additional four core concessions were acquired via option agreements, to bring the total land position to 1000 hectares. Total acquisition costs to acquire 100% of the four privately held concessions are US $ 530,000 over a three to four year period. There are no royalties.
With recent additional staking, the Company now controls approximately 3204 hectares of this attractive new precious metal district.
First phase field programs demonstrated the existence of at least seven zones of mineralization. The Company designed an aggressive exploration program at El Tesoro which commenced in October 2003, including road building, mechanical trenching, and drilling.
The drill program, which commenced in March 2004, was designed to: 1) confirm the down-dip extension of mineralization in five of the seven currently known gold bearing zones, 2) perform limited reconnaissance drilling in areas with minimal surface exposure, 3) increase geological knowledge of the controls and influences of mineralization. The program succeeded in fulfilling all three objectives.
Drilling and related surface sampling have shown that the El Tesoro property contains an intensely mineralized system, strongly anomalous in gold throughout. This 1800 metre, first phase drill program tested less than 15% of the apparent strike length of the presently known 2.5 kilometre mineralized system. Based on the results of the drill program, Northair increased its land position from 1000 to 3204 hectares.
Drill Program Discussion:
Please read the attached table for a complete summary of first phase drill results, including: drill plan, selected sections, property claim map and geology map.
Twelve drill holes in the A and E Zones, over a combined strike length of 130 metres, successfully tested the down-dip extension of strong gold and silver mineralization in a rhyolite intrusive exposed in shallow underground workings and surface trenching. Both zones remain open along strike and down dip.
Drilling of the B, C and D Zones was more reconnaissance in nature, with the longest holes of the program in the B and C Zones. Positive results were obtained from the northernmost hole of the B Zone, which encountered a significant intersection of the favourable rhyolite intrusive with good gold and silver values. The hole targeted to intersect the C Zone did not return significant gold values and apparently failed to penetrate the zone. Drilling at the D Zone showed wide, strongly silicified breccia zones, with two holes returning significant gold values over narrow widths. The Company is particularly encouraged by the results from this zone.
Exploration Plans:
Based on the recent drill results, Northair has embarked on an expanded exploration program at El Tesoro designed to formulate the optimum follow-up drill program on the property. Over the next three months, the Company will continue to explore the seven known zones, while expanding the exploration program on the remainder of the property.
Detailed geological mapping and sampling, working outward and along strike from known zones, has commenced. Road access to G zone will be completed to enable mechanical trenching and geological surveying and the F zone will be further sampled via trenching. Trial geochemical and geophysical surveys are proposed to locate possible overburden covered zones and extensions of known zones.
Continued property wide geological mapping and reconnaissance sampling will be undertaken, as only approximately 10% of the newly expanded, and geologically prospective, land package has been investigated.
Prior to the March 2004 drill program, Northair had taken more than 750 samples on the project, 190 of these taken from trenches. Highlights of hand trenching include; 3 m of 18.89 g/t gold from the A Zone and 10 m of 9.00 g/t gold from the B Zone. A mechanical trenching program successfully extended previously known zones of mineralization, exposing apparent full widths, and providing additional outcrops for geologic mapping band sampling. Examples of mechanical trenching results include; 6 m of 27.04 g/t gold and 702.2 g/t silver from the A Zone and 3 m of 22.42 g/t gold and 72.0 g/t silver from the E Zone. Full mechanical trenching results are provided in the table called “View Project Maps,” of the El Tesoro Project section of the International North Mines Ltd. website.
Metallurgy:
Testing procedures completed to date include both cyanide leach tests as well as metallic screen sieve analyses. A total of 18 samples were analyzed to determine gold and silver recoverability by cyanide leach tests, with an average recovery of 97.8% recovery for gold, and 50.2% recovery for silver. Gold recoveries ranged from 96% to 100%, and silver ranged 35% to 87.9%. The procedure simulates an actual vat leach style recovery plant.
Three samples were also run for metallic screen analysis. Results revealed that the majority of the gold in mineralized rock from El Tesoro is in a minus 100 micron fraction. Although visible, fine – grained free gold is common, the screen tests indicate that sample results should not be influenced by a potential “nugget effect”.
PRESS RELEASE
INTERNATIONAL NORTHAIR MINES LTD.
April 27, 2004
Suite 860 - 625 Howe Street, Vancouver, B.C. V6C 2T6 CANADA
Telephone: (604) 687-7545 Facsimile: (604) 689-5041 #04-07_______________
NORTHAIR STAKES LA JOYA GOLD PROJECT: DURANGO, MEXICO
International Northair Mines Ltd. (TSXV:INM) has acquired an additional precious metals property located in the state of
Durango, Mexico. The “La Joya” Project is located along the western flanks of the Sierra Madre Occidental province,
approximately 110 kilometers southwest of the city of Durango. La Joya was identified and staked by Company geologists as
a result of Northair’s ongoing generative exploration program. This acquisition has expanded Northair’s current portfolio of
early stage, gold and silver projects in Mexico to four, including the highly prospective El Tesoro Project, where an expanded
exploration program continues.
The wholly owned concession covers 800 hectares, and lies in a geologic setting similar to the Company’s Las Moras and El
Tesoro properties. La Joya has the potential to contain both high grade vein as well as bulk tonnage gold - silver deposits.
Within the property position, geologists have identified a possible rhyolite dome with outlying rhyolite dykes. Two zones of
alteration and mineralization have been identified to date. The A Zone contains a rhyolite dyke, ranging from 5 – 20 meters in
width, which has been traced over a strike length of 130 meters, and is open in both directions. Within the dyke are numerous
low sulfidation quartz veins ranging from 1 – 1.5 meters in width. Eleven grab samples taken from the A Zone have returned
gold values ranging from anomalous to 1.57 g/t.
The B Zone lies about 300 metres west of the A Zone, and has been traced by intermittent outcrops over a strike length of 250
metres, and remains open in both directions. Average widths of the structure range from approximately 3 to over 50 meters. A
total of 15 representative panel reconnaissance and continuous chip samples have been taken from the B Zone, with very
encouraging gold and silver results. Six samples exceeding 1 g/t gold are listed below:
Sample Au g/t Ag g/t
LBR-10 4.58 36.3
LBR-11 1.40 50.4
LBR-12 1.71 52.0
SP-4 4.58 66.3
SP-5 2.12 231.0
SP-6 4.01 60.5
The Company is encouraged by these initial results and has commenced a detailed geological mapping and sampling program.
The exploration program is under the direction of Mr. Jim Robinson, Vice President of the Company, who is a Qualified
Person as defined by NI 43-101.
Northair’s Mexican generative exploration program has been highly successful in acquiring and joint venturing six quality
projects over the past five years, including drilling of some of these projects by major mining companies. The Company has an
annual generative exploration budget exceeding $300,000CDN to maintain its first-mover advantage.
ON BEHALF OF THE BOARD,
INTERNATIONAL NORTHAIR MINES LTD.
Everything he says is true but I believe it is fairly normal for drill hole grades to be less than trench samples, mainly because trench samples are usually "oh look some gold, let's sample that.". The results were a little dissapointing to me in regards to the length of intercepts. After reviewing some of the prior press releases I have it in my mind that the G-zone may be the only/main area with potential for large intercept mineralization while the other ares will be more veinlike. The G zone hasn't been explored yet but they should have road access to it now.
amarksp,
Thanks for posting.
rt
International Northair Mines (INM : TSX-V : C$0.85) - HOLD - Target price: NA
Graeme Currie
Comment: International Northair initial drill results from El Tesoro below surface values
International Northair is a junior currently focused on the El Tesoro project. The initial phase of drilling was conducted in Q1/04 and yesterday the results were released. We calculate that the gold grade multiplied by thickness for the four zones tested average at 4.52 g/t Au, with the A Zone having the highest average of 7.45 g/t Au. If the higher-grade interval in hole 04-006 is removed from the calculation, the average grade for all zones declines to 3.78 g/t Au, thus this one hole clearly influences the overall results. As compared to the surface chip samples from the appropriate zones all grades fell well shy of initial surface values, thus there may have been some form of surface enrichment, though this is only conjecture at present. We have also reviewed mechanical trench assay values from the A Zone previously reported by the company. Again, the drill assays reported yesterday fall well shy of trench values save for holes 006 and 020. Additional exploration and drilling is clearly warranted for this project and is planned – however, the results released to date fall shy of our expectations regarding grade. Thus, we are lowering our recommendation from Speculative Buy to HOLD
Whats your opinion of the news?
looks like your the only one who does :(
Cannacord dumping bigtime.
They have case for another round of drilling, but would guess that after that they have to go to the market.
I like the results and will likely add more if the share price continues to slip.
Anyone know how INM is doing for cash and burn-rate????
Summary of El Tesoro First Phase Drill Program, March 2004
A zone
Depth Int- Au Ag Total
m erval g/t g/t depth
m m
TRC-04-001
21.34 -- 25.15 3.81 5.10 26.5 76.2
incl.
21.34 -- 21.52 2.29 7.69 35.6
and
28.19 -- 28.96 0.76 1.98 7.9
TRC-04-002
18.29 -- 22.10 3.81 4.85 26.8 54.86
and
29.72 -- 30.48 0.76 1.28 3.6
TRC-04-003
11.43 -- 15.24 3.81 mine 45.72
workings
15.24 -- 16.76 1.52 3.26 30.3
and
32.00 -- 35.05 3.05 1.48 31.7
TRC-04-004
22.10 -- 22.86 0.76 1.10 6.6 45.72
TRC-04-005
48.77 -- 51.05 2.29 6.13 24.6 76.2
incl.
48.77 -- 49.53 1.52 8.22 30.1
TRC-04-006
17.53 -- 22.10 4.57 16.87 122.3 45.72
22.10 -- 23.62 1.52 mine workings
23.62 -- 25.15 1.53 6.33 48.0
TRC-04-020
73.15 -- 76.20 3.05 13.60 18.4 86.87
incl.
73.15 -- 74.01 0.76 46.90 42.0
E zone
Depth Int- Au Ag Total
m erval g/t g/t depth
m m
TRC-04-007
15.24 -- 16.76 1.52 3.04 15.9 54.86
TRC-04-008
17.53 -- 19.81 2.29 3.41 14.6 37.34
TRC-04-009
13.72 -- 15.24 1.52 1.52 7.7 36.58
and
23.62 -- 27.43 3.81 4.09 15.8
incl.
23.62 -- 25.91 2.29 5.52 21.4
or incl.
24.38 -- 25.15 0.77 9.82 26.0
TRC-04-010
16.76 -- 19.05 2.29 4.33 9.7 40.39
incl.
17.53 -- 18.29 0.76 10.05 15.8
and
29.72 -- 32.00 2.29 2.38 10.0
TRC-04-011
30.48 -- 31.24 0.76 1.46 8.3 76.2
and
55.63 -- 59.44 3.81 3.20 23.3
incl.
57.91 -- 59.44 1.52 6.12 41.9
or incl.
57.91 -- 58.67 0.76 10.80 69.6
B zone
Depth Int- Au Ag Total
m erval g/t g/t depth
m m
TRC-04-012
103.63 -- 105.16 1.52 2.64 2.6 228.6
and
109.73 -- 112.78 3.05 2.92 10.8
and
140.21 -- 140.97 0.76 3.76 6.3
and
161.54 -- 162.31 0.76 1.23 2.8
and
170.69 -- 171.45 0.76 1.33 2.2
TRC-04-013
121.16 -- 131.06 9.91 3.38 17.0 170.69
incl.
124.97 -- 128.02 3.05 7.40 14.3
or incl.
124.97 -- 126.49 1.52 10.90 52.9
TRC-04-019
NSV 239.27
D zone
Depth Int- Au Ag Total
m erval g/t g/t depth
m m
TRC-04-014
33.53 -- 35.05 1.52 6.87 10.9 88.39
incl.
34.29 -- 35.05 0.76 11.80 13.0
TRC-04-015
45.72 -- 48.01 2.29 2.27 7.0 85.34
incl.
45.72 -- 46.48 0.76 5.18 9.6
and
51.05 -- 51.82 0.76 11.20 56.2
and
64.01 -- 64.77 0.76 1.17 7.8
and
70.10 -- 70.87 0.76 2.16 15.8
TRC-04-016
NSV 80.77
TRC-04-017
NSV 50.29
NSV = No significant value.
New press release out...
EL TESORO FIRST PHASE DRILL PROGRAM YIELDS HIGH GRADE GOLD VALUES
LAND POSITION EXPANDED
International Northair Mines Ltd. (TSXV:INM) has completed a first phase, reverse circulation drill program at the El Tesoro Project, Durango State, Mexico. Based on the encouraging results obtained, Northair is planning a follow up drill program.
Highlights from the program include:
• 16.87 g/t gold and 122.3 g/t silver over 4.57m in the A Zone
• 13.60 g/t gold and 18.4 g/t silver over 3.05m in the A Zone
• 10.80 g/t gold and 69.6 g/t silver over 0.76m in the E Zone
• 3.38 g/t gold and 17.0 g/t silver over 9.91 m in the B Zone
• 11.20 g/t gold and 56.2 g/t silver over 0.76m in the D Zone
The drill program was designed to: 1) confirm the down-dip extension of mineralization in five of the seven currently known gold bearing zones, 2) perform limited reconnaissance drilling in areas with minimal surface exposure, 3) increase geological knowledge of the controls and influences of mineralization. The program succeeded in fulfilling all three objectives.
Drilling and related surface sampling have shown that the El Tesoro property contains an intensely mineralized system, strongly anomalous in gold throughout. This 1800 metre, first phase drill program tested less than 15% of the apparent strike length of the presently known 2.5 kilometre mineralized system.
Based on the results of the drill program, Northair has increased its land position from 1000 to 3204 hectares. Drill Program Discussion Please read the attached table for a complete summary of first phase drill results. 12 drill holes in the A and E Zones, over a combined strike length of 130 metres, successfully tested the down-dip extension of the strong gold and silver mineralization in a rhyolite intrusive exposed in shallow underground workings and surface trenching. Both zones remain open along strike and down dip.
Drilling of the B, C and D Zones was more reconnaissance in nature, with the longest holes of the program in the B and C Zones. Positive results were obtained from the northernmost hole of the B Zone, which encountered a significant intersection of the favourable rhyolite intrusive with strong gold and silver values. The hole targeted to intersect the C Zone did not return significant gold values and apparently failed to penetrate the zone. Drilling at the D Zone showed wide, strongly silicified breccia zones, with two holes returning significant gold values over narrow widths. The Company is particularly encouraged by the results from this zone.
Exploration Plans
Based on these drill results, Northair has embarked on an expanded exploration program at El Tesoro designed to formulate the optimum follow-up drill program on the property. Over the next three months, the Company will continue to explore the seven known zones, while expanding the exploration program on the remainder of the property.
Detailed geological mapping and sampling, working outward and along strike from known zones, has commenced. Road access to G zone will be completed to enable mechanical trenching and geological surveying and the F zone will be further sampled via trenching. Trial geochemical and geophysical surveys will also be conducted to locate possible overburden covered zones and extensions of known zones.
Continued property wide geological mapping and reconnaissance sampling will be undertaken, as only
approximately 10% of the newly expanded, and geologically prospective, land package has been investigated.
chin up mate, I recall that last year right around this time I was at my pf lows, just hoping that this year will turn around the same.
silver now 6.74 seeesh. ficking hell.
Start selling to who? I might as well just hold my illiquid pos's...
No, apparently the NR has to go around each board member for input. Which is a little worrisome as it makes we wonder what they have. Results could be complicated or not straightforward, hence not layman friendly.
mine too, watch for 389 on the gold and if it gets there start selling. Otherwise I am still positive.
You still expect news today ?
My account is bleeding again today and I'm getting tired of it.
Might have to change my name to McMadburger as I picked some more up today.
If thats what you think it is then this play could be worth more than I thought! (g)
Yep, new look and feel at the INM website...
bunch of new photos...
http://www.northair.com/international/projects-eltesro.php
especially like this picture of the work crew resting next to their stash of cocaine financed by we generous INM shareholders..., was wondering where all my hard earned $ were going, well they seem a deserving lot...
And they are optioning it:
Northair Joint Ventures Sierra Rosario Property With
Sparton
TORONTO, ONTARIO--(CCNMatthews - Mar 18, 2004) - International
Northair Mines Ltd. (TSXV: INM) ("Northair") and Sparton
Resources Inc. (TSXV: SRI) ("Sparton"), have signed a binding
Option Agreement ("the Agreement") whereby Sparton can earn a 51%
interest in Northair's Sierra Rosario project. The 500 hectare
project area lies along the western flanks of the Sierra Madre
Occidental geological province in the state of Sinaloa, Mexico
and was staked by Northair as part of the company's ongoing,
highly successful, generative exploration activities in the
region.
Sierra Rosario covers at least six gold and silver occurrences
discovered by Northair's exploration staff. The "San Rafael Zone"
contains strong gold-silver mineralization in a rhyolite porphyry
that has been traced on surface for over 150 metres along strike,
and has an exposed apparent width of up to 40 metres. The zone is
open in both directions along strike. Twenty-three chip channel
samples taken from this zone by Northair averaged 181 g/t silver
and 0.32 g/t gold. Eight grab samples from this zone returned
1.79 g/t gold and 200 g/t silver with a high of 10.79 g/t gold
and 711 g/t silver.
Sparton's first phase of exploration, which is expected to begin
in May 2004, will consist of further geological mapping of the
concession, and detailed mapping and sampling of the San Rafael
Zone and other occurrences within the property area. Subsequent
programs, as warranted, may include road construction, mechanical
trenching and possibly drilling, likely using reverse circulation
methods. Sparton will be utilizing Northair's Mexican exploration
expertise to assist in the initial phases of exploration on the
Sierra Rosario property.
The terms of the Agreement require Sparton to earn its 51%
interest by paying Northair $130,000(Cdn) in cash, issuing
275,000 common shares and incurring $800,000(Cdn) in exploration
expenditures over a four year period. The Agreement is subject to
regulatory approval.
"Sparton is pleased to be associated with Northair's seasoned
team of explorationists and developers", stated Lee Barker,
Sparton's president. "We have monitored their aggressive
generative exploration programs in Mexico, and wish Northair
every success in its first-phase drill program on its 100% owned
El Tesoro project in Durango State."
Fred G.Hewett, Northair's President, stated: "Northair is
delighted to be working again with members of the Sparton team.
They have a long and successful history of project exploration,
development, and mining in Mexico in their previous positions
with several Canadian resource companies, including Lacana Mining
Corporation."
/T/
ON BEHALF OF THE BOARDS OF:
INTERNATIONAL NORTHAIR MINES Ltd.
Per:
"Fred G. Hewett"
----------------------
Fred G. Hewett, P.Eng.
President
SPARTON RESOURCES INC.
Per:
"A. Lee Barker"
------------------------------
A. Lee Barker, P.Eng. P. Geol.
President
/T/
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this press
release. This news release may contain forward looking statements
which are not historical facts, such as ore reserve estimates,
anticipated production or results, sales, revenues, costs, or
discussions of goals and exploration results, and involves a
number of risks and uncertainties that could cause actual results
to differ materially from those projected. These risks and
uncertainties include, but are not limited to, metal price
volatility, volatility of metals production, project development,
ore reserve estimates, future anticipated reserves and cost
engineering estimate risks, geological factors and exploration
results. See the Company's AIF Report and filings for a more
detailed discussion of factors that may impact expected results.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
International Northair Mines Ltd.
604-687-7545 OR TOLL FREE 1-888-338-2200
http://www.northair.com/international/
or
Sparton Resources Inc.
416-947-0907
http://www.spartonres.ca
--------------------------------------------------------------------------------
Here is a description of one of their other projects taken off the website. It looks like it might be a good silver target.
Sierra Rosario Project, Sinaloa, Mexico
Sierra Rosario is an early stage exploration project that has returned very encouraging results from multiple zones of mineralization.
Sierra Rosario was acquired by staking in April, 2002 (see news release) and is Grupo Northair’s sixth project in Mexico. Sierra Rosario lies along the western flanks of the Sierra Madre Occidental geological province and covers at least six gold and silver occurrences discovered by Northair exploration staff as a result of the Company's ongoing generative exploration program.
The Sierra Rosario Project is located approximately 25 kilometers northwest of Choix, Sinaloa; and 40 kilometers east of Alamos, Sonora. Both towns have a strong mining history. The Company’s geologists were initially introduced to the area by local gambusinos who described drainages with rich placer gold. A roughly 1.5 kilometer stretch of a main drainage within the property contains dozens of historic placer workings, and most of the smaller arroyos within the southern portion of the property also contain placer gold. Gambusinos have also produced gold from soils and colluvium in this southern area which may overlie mineralized bedrock.
The property contains Cretaceous age limestone intruded by upper Cretaceous granodiorite belonging to the
Sinaloa batholith. These older rocks are locally overlain by a fine-grained silicic volcanic unit that hosts much of the mineralization. The volcanics have been intruded by numerous phases of granodiorite dikes, dacite porphyry and rhyolite porphyry. The age of the volcanics and younger intrusives is interpreted as being lower Tertiary. Although the granodiorite dikes are intensely altered, mineralization appears to be more related to the dacite and rhyolite porphyries. The property is intersected by numerous regional deep seated fault systems of variable orientation, some of which are important conduits for localizing mineralizing fluids.
Three deposit types have been identified to date:
1. Disseminated and structurally controlled Ag-Au (+Cu, Pb, Zn) in altered rhyolite porphyry
2. High sulfidation, structurally controlled gold in volcanic and dacite porphyry
3. Polymetallic mantos replacements in limestone
The “San Rafael Zone” is the principle target defined to date, and occurs in an intensely altered rhyolite porphyry in the northern part of the concession. An exploration program was recently completed (see news release) on the San Rafael Zone. The program, consisting of geologic mapping and sampling, has shown the known surface expression of the San Rafael Zone of mineralization to be approximately 200 x 70 meters within an intensely altered rhyolite porphyry. Mineralization is epithermal, and contains strong silica replacement and quartz veining with multiple orientations. Only about 20% of the zone is exposed in workings and outcrops, limiting the ability to thoroughly sample the zone without a mechanical trenching program, although there are numerous small “open pits” and several small adits made by local miners within the zone. Most samples taken by the Company were 5 meters in width but range from 3 to 7 meters. An effort was made to orient samples perpendicular to the strike of mineralization using standard industry accepted sampling techniques. Where possible, sampling was continuous channel samples for composite averages, however this attempt was constricted due to limited outcrop. Sample weights averaged approximately 2.5 kg, with assaying performed by ALS Chemex Labs, Inc. The average for the twenty-three samples taken is 181 g/t silver and 0.321 g/t gold with anomalous copper, lead and zinc values.
Five additional zones of structurally hosted gold mineralization have been identified within the property. These zones are associated with dacite porphyries and have been interpreted as a primary source of much of the placer gold. True widths of these mineralized zones are generally difficult to determine due to a thin veneer cover of soil and colluvium, but surface expression of alteration frequently exceeds 20 meters. A total of 26 samples have been taken from these five zones, with eleven samples reporting greater than 100 ppb gold and a high of 5.48 g/t. Assaying indicates the presence of coarse free gold with a strong nugget effect
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
117
|
Created
|
07/08/03
|
Type
|
Free
|
Moderators |
Inmed Pharmaceuticals (IMN) Company Spotlight
A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids. InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects. InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
Investment Highlights
Bioinformatics: Proprietary Drug / Disease Targeting Tool
InMed’s has developed a computer-based program to assist in the identification of novel cannabinoids using: (i) comprehensive algorithms to integrate data from numerous bioinformatics databases, (ii) a database on the structure of currently approved pharmaceutical products, and (iii) an extensive database on over 90 individual cannabinoid drugs found in cannabis. InMed’s data included in its bioinformatics assessment tool are derived from both public and propriety based sources and include information on: Protein-Protein interactions, Gene Regulation, Epigenetic modification, Cell signal networks, and Metabolomics
Biosynthesis
Most of us are familiar with the two main bio-active ingredients produced by the cannabis (marijuana) plant, namely THC and CBD. In reality, however, there are 90+ cannabinoids in the plant that could have medical value but are too hard to research due to the fact that they only appear in trace amounts in each plant. InMed has developed, patented, and intends to commercialize a process for producing all 90+ cannibinoids using genetically engineered bacteria to create bioidentical copies of these substances. Not only is their process less costly but it also produces these cannabinoids in large quantities at pharmaceutical-grade purity. The following link provides a clear explanation of the process in laymen's terms.
Biosynthesis: The Science That May Unlock the Medical Potential of Cannabis
InMed is building a robust product pipeline through its proprietary discovery platform and research & product development programs. The company continues to seek innovative product candidates for the treatment in following therapeutic areas:
|
|
InMed's pipeline currently includes two drug candidates in preclinical development: INM-750 for the treatment of epidermolysis bullosa (EB); and INM-085 for the treatment of glaucoma.
INM-750
Referred to as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. Through the development of INM-750, InMed is attempting to address this significant unmet medical need, for which there is no approved treatment or cure. INM-750 replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
Market Potential - Amicus Therapeutics recently acquired Scioderm, Inc. and its lead EB drug candidate, Zorblisa™, for $847 million. Notably, Scioderm's sole clinical asset was Zorblisa.
JP Morgan and Cowen Research Reports estimate that peak sales for Zorblisa could reach $900 million to $1.2 billion.
INM-085
INM-085 is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure.
Market Potential - The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease. Worldwide, glaucoma represents a market of $5.6 billion.
Leadership
InMed's management team has well over a century of combined experience in the biopharmaceutical space. Together, the professionals comprising this team are guiding InMed into exciting opportunities in the cannabis-pharma sector.
Eric A. Adams, President & CEO
Eric Adams is a seasoned biopharmaceutical executive with over 25 years of experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.
He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana aerospace industry, most recently with Metal Form, Inc., a privately held aerospace manufacturing company, where he served as president and CEO from 1987 to September of 1999.
Dr. Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer
Dr. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.
Dr. Ado Muhammed, MD, DPM, MFPM, Chief Medical Officer
Dr. Ado Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed's received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.
Alexandra D.J. Mancini, M.Sc., Senior Vice President, Clinical and Regulatory Affairs
Alexandra Mancini has over 30 years' of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Ms. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Ms. Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions. Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.
Jeff Charpentier, CFO, Chief Financial Officer
Jeff Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.
InMed Pharmaceuticals, Inc. | NetworkNewsWire |
NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
Corporate Presentation
https://www.inmedpharma.com/site/assets/files/1343/jan-cp-2017-2.pdf
InMed Pharmaceuticals is currently developing two products in its drug pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.
Epidermolysis Bullosa (EB) is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma. Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins (or, proteins) in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM-750 will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.
INM-750 includes multiple cannabinoids as the active ingredients:
INM-085
Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.
INM-085 will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM-085 have been selected to reduce the elevated intra-ocular pressure (IOP) in the affected eyes and provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues. INM-085 is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM-085.
Proposed Targets to Develop Drugs From Cannabis and Other Botanical Sources
Dermatology
Ocular
Pain and Inflammation
CNS
Respiratory
Metabolic Disease
The majority of pharmaceutical and academic research & development activities being performed with cannabis revolves around the understanding of its biologically active ingredients, the Cannabinoids
Currently there are 90+ cannabinoids that have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for unique pharmacological effects.
There are three general types of cannabinoids: herbal cannabinoids which occur uniquely in the cannabis, endogenous cannabinoids produced in the bodies of humans and animals and synthetic cannabinoids produced in the laboratory.
Cannabinoid Receptors
Before the 1980s, it was often speculated that cannabinoids produced their effects through nonspecific interaction with cell membranes, instead of interacting with specific receptors. The discovery of the first cannabinoid receptors in the 1980s helped to clarify their role. These receptors are common in animals, and have been found in mammals, birds, fish and reptiles. There are currently two known types of cannabinoid receptors, called CB1 and CB2.
CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are essentially absent in the medulla oblongata, the part of the brain that is responsible for respiratory and cardiovascular functions. Thus, there is not a risk of respiratory or cardiovascular failure as there is with many other drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.
CB2 receptors are almost exclusively found in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis.
The protein sequences of these two receptors are about 45% similar. In addition, minor variations in each receptor have been identified. There is some indication that other receptors exist, but none have been confirmed. Cannabinoids bind reversibly and stereo-selectively to the cannabinoid receptors. The affinity of an individual cannabinoid to each receptor determines the effect of that cannabinoid. Cannabinoids that bind more selectively to certain receptors are more desirable for medical usage.
Herbal Cannabinoids
Herbal cannabinoids are nearly insoluble in water but soluble in lipids, alcohols and other non-polar organic solvents. All herbal cannabinoids are derived from their respective 2-carboxylic acids (2-COOH) by decarboxylation that is, catalyzed by heat, light, or alkaline conditions. Herbal cannabinoids occur naturally only in the cannabis plant, and are concentrated in a viscous resin that is produced in glandular structures known as trichomes. In addition to cannabinoids, the resin is rich in terpenes, which are largely responsible for the odor of the cannabis plant.
There are over ninety known herbal cannabinoids. Of these, tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent and have received the most attemtion. Other common cannabinoids include:
CBG | Cannabigerol |
CBC | Cannabichromene |
CBL | Cannabicyclol |
CBN | Cannabidiol |
CBV | Cannabivarol |
THCV | Tetrahydrocannabivarin |
CBDV | Cannabidivarin |
CBCV | Cannabichromevarin |
CBGV | Cannabigerovarin |
CBGM | Cannabigerol Monoethyl Ether |
THC is the primary psychoactive component of the plant. Medically, it appears to mediate pain and to be neuroprotective. THC has a greater affinity for the CB1 receptor than for the CB2 receptors. Its effects are perceived to be more cerebral. CBD is not psychoactive, and appears to mediate the euphoric effect of THC. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea. CBD has a greater affinity for the CB2 receptor than for the CB1 receptor. It is perceived to have more effect on the torso than on the brain or CNS. Cannabinoids were first discovered in the 1940s. The structure of THC was first determined in 1964. Due to molecular similarity and ease of synthetic conversion, it was originally believed that CBD was a natural precursor to THC. However, it is now known that CBD and THC are produced independently in the cannabis plant. Cannabis plants can exhibit wide variation in the quantity and type of cannabinoids they produce. The mixture of cannabinoids produced by a plant is known as the plant’s cannabinoid profile. Selective breeding has been used to control the genetics of plants and modify the cannabinoid profile. For example, strains of hemp, which are used as fiber, are bred such that they are low in psychoactive chemicals like THC. Strains used in medicine are often bred for high CBD content, and strains used for recreational purposes are usually bred for high THC content, or for a specific chemical balance. Some strains of more than 20% THC have been created. Cannabinoids can be administered by: smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, although some is stored in fat. Cannabinoids can be separated from the plant by extraction with organic solvents. However, to produce high purity, cannabinoid chemical synthesis or semisynthesis is generally required.
University of British Columbia
Department of Chemical & Biological Engineering
Vancouver Campus
2360 East Mall
Vancouver, BC Canada V6T 1Z3
Department of Pharmaceutical Sciences
Vancouver Campus
2405 Westbrook Mall
Vancouver, BC, Canada V6T 1Z3
University of Debrecen
Research Center for Molecular Medicine, Department of Physiology
1H-4032 Debrecen, Nagyerdei krt. 98
Hungary
ALERT
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |